It just requires focus, discipline, and a respect for the delicate nature of the compounds you're working with
Both are E3 ubiquitin ligases that drive muscle protein breakdown (Sacheck et al., 2004)
Model Is the work done in isolated cells, in animals, or in humans Human data carry more weight for decisions that depend on actual outcomes Material Is the study using GHK Cu, GHK alone, or a vague copper peptide Does the methods section specify how the complex was prepared or verified Endpoint Is the primary outcome a molecular marker, a histology readout, or a clear clinical change such as wound closure speed or graded skin appearance Biomarkers can be useful, but they are not interchangeable with clinical outcomes Comparator Is there a placebo or vehicle control Is there a standard of care or another active comparator Exposure Are the doses or concentrations used in the experiment close to what could be achieved in a practical setting Some in vitro work uses concentrations that are orders of magnitude higher than those ever used in people Funding and conflicts Who funded the work Are there obvious commercial ties These factors do not automatically invalidate a study, but they do guide how skeptical a reader should be
Individual responses vary
Neurodegenerative diseases While experimental data is still limited, DSIPs potential role in protecting the brain from the ravages of diseases such as Alzheimers and Parkinsons warrants further exploration
